- Drugs
- Thursday, 19 Sep 2019
Aphria Inc Launches Plant Positivity Social Impact Platform with Evergreen
Aphria Inc. announced the launch of its new social impact platform, Plant Positivity. The company partnered with not-for-profit Evergreen which will create six new garden spaces at Evergreen Brick Works.
Aphria, Inc. is engaged in the production and supply of medical cannabis. It operates through three reportable segments including cannabis operations, distribution operations, and business under development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis. The Distribution Operations segment are carried out through its wholly owned subsidiaries ABP, FL Group, and CC Pharma. The Distribution under Development segment includes operations in which the firm has not received final licensing or has not commenced commercial sales from operations. The company offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois. The Company is also engaged in the research and development, and commercial production of cannabis oil. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada. Aphria’s subsidiaries include Pure Natures Wellness Inc. that are engaged in the production and distribution of medical marijuana, and Cannway Pharmaceuticals Ltd., which specializes in offering support services to veterans and their first responders.
Related Industry Updates
Prostate Cancer Therapeutics Market is expected to grow US$ 28,425.27 million by 2030
Dec 12, 2023
Angelini Pharma and Quiver Partner to Advance Genetic Epilepsies
Feb 25, 2026
Clinical Trial Imaging Market is expected to reach US$ 2,480.32 million by 2028
May 23, 2023
Aphria Inc.'s Jamaican Subsidiary, Marigold, Receives Retail Herb House Licence
Sep 17, 2019
Pivot Pharma Launches Canadian Cannabis and Nutraceutical Manufacturing Facility
Nov 25, 2019
Infectious Disease Therapeutics Market is expected to reach US$ 1,67,883.93 million by 2030
Jan 25, 2024
FDA Clears ACCRUFeR® (ferric maltol) for Iron Deficiency
Feb 18, 2026